Infectious Disease Therapy

RFI-641 effective against respiratory syncytial virus

Published in TB and Outbreaks Week, April 16th, 2002

by Michael Greer, senior medical writer - Researchers in the United States say that a novel compound shows promise for the treatment of illnesses caused by respiratory syncytial virus.

"Human respiratory syncytial virus (RSV), a paramyxovirus, is a major cause of acute upper and lower respiratory tract infections in infants, young children, and adults," explained Clayton C. Huntley and colleagues at Wyeth-Ayerst Research in Pearl River, New York, Virion Systems, Inc., in Rockville, Maryland, and Baylor College of Medicine in Houston, Texas.

The compound dubbed RFI-641 is highly and selectively active against RSV, Huntley and coauthors found.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-04-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry